A TRISPECIFIC ROR1 X CD3 T CELL ENGAGER MEDIATES IN VITRO TUMOR CELL KILLING AND IN VIVO TUMOR ERADICATION

被引：1

作者：

Chatterjee, Bithi ^{[1
]}

Snell, Daniel ^{[1
]}

Hess, Christian ^{[1
]}

Brock, Matthias ^{[1
]}

Spiga, Fabio ^{[1
]}

Simonin, Alexandre ^{[1
]}

Gunde, Tea ^{[1
]}

Warmuth, Stefan ^{[1
]}

Weinert, Christopher ^{[1
]}

Bassler, Nicole ^{[1
]}

Kirk, Niels ^{[1
]}

Schumacher, Nina ^{[1
]}

Mahler, Dana ^{[1
]}

Yaman, Yasemin ^{[1
]}

Bommer, Bettina ^{[1
]}

Gambino, Giorgio ^{[1
]}

Giezendanner, Noreen ^{[1
]}

Kuettner, Benjamin ^{[1
]}

Flueckiger, Naomi ^{[1
]}

Heiz, Robin ^{[1
]}

Wagen, Sandro ^{[1
]}

Diem, Dania ^{[1
]}

Zeberer, Julia ^{[1
]}

Urech, David ^{[1
]}

机构：

[1] Numab Therapeut, Wadenswil, Switzerland

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

844

引用

页码：A885 / A885

页数：1

共 50 条

[31] ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Zhang, Suping
Chen, Liguang
Cui, Bing
Chuang, Han-Yu
Yu, Jianqiang
Wang-Rodriguez, Jessica
Tang, Li
Chen, George
Basak, Grzegorz W.
Kipps, Thomas J.
PLOS ONE, 2012, 7 (03):
[32] CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation
Willems, A
Schoonooghe, S
Eeckhout, D
De Jaeger, G
Grooten, J
Mertens, N
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) : 1059 - 1071
[33] FDA approves first DLL3 x CD3 bispecific T-cell engager for lung cancer
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (07) : 487 - 487
[34] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
Reed, Daniel R.
Lum, Lawrence G.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
[35] A Novel Humanised ROR1 Bi-Specific T-Cell Engager Molecule for the Treatment of Chronic Lymphocytic Leukaemia
Gohil, Satyen Harish
Harrasser, Micaela
Paredes-Moscosso, Solange R.
Nathwani, Amit C.
Della Peruta, Marco
BLOOD, 2016, 128 (22)
[36] A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment
Gohil, Satyen
Paredes-Moscosso, Solange Rosa
Harrasser, Micaela
El-Kholy, Mohamed
Morris, Emma
Nathwani, Amit
Della Peruta, Marco
BLOOD, 2017, 130
[37] A single administration of DNA-encoded trispecific T cell engager (DTriTE) targeting EGFRvIII, IL13Ra2, and CD3 shows complete tumor clearance in an orthotopic challenge model of heterogeneous GBM
Park, Daniel Hongil
Bhojnagarwala, Pratik
Liaw, Kevin
Bordoloi, Devivasha
Gary, Ebony N.
Weiner, David B.
CANCER RESEARCH, 2023, 83 (07)
[38] An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors
Gohil, Satyen Harish
Paredes-Moscosso, Solange Rosa
Harrasser, Micaela
Vezzalini, Marzia
Scarpa, Aldo
Morris, Emma
Davidoff, Andrew M.
Sorio, Claudio
Nathwani, Amit Chunilal
Della Peruta, Marco
ONCOIMMUNOLOGY, 2017, 6 (07):
[39] Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo
Fallarino, F
Grohmann, U
Bianchi, R
Vacca, C
Fioretti, MC
Puccetti, P
JOURNAL OF IMMUNOLOGY, 2000, 165 (10): : 5495 - 5501
[40] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
Cugnetti, Ana Paula
Liu, Haizhen
McNeeley, Patricia
Wheeler, Christina
Lucas, Matthew
Xing, Charles
Joyner, Solmarie
Johnson, Kyrie
Woodard, Kathryn
Zhou, Wei
Chang, Cathy
Frey, Gerhard
Boyle, William J.
Short, Jay M.
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 4 5 →